Taxonomy: Tariff Line Affected - 3001
Glands Etc Dry & Ext, Heparin, Hum Etc Subst Nesoi
China: VAT rebates for more than 2600 products
Description
On 3 June 2009, the government of China raised the Value Added Tax (VAT) rebates for designated textile and garment exports. Exporters of the benefiting products may recuperate part of the VAT included in intermediate products.China: Increased VAT rebates for food, textiles, wood products, metals, chemicals and machinery
Description
On 1 December 2008, the government of China raised the Value Added Tax (VAT) rebates for designated exports. Exporters of the benefiting products may recuperate up to 80 percent of the VAT included in intermediate products.Argentina extends its import-export-balance policy to the pharmaceutical industry
Description
On March 10th, 2011, the Argentinean Ministry of Industry adopted a “verbal” measure, whereby imports of cars and inputs used by local car producers would be limited to the value of local production that they export (see GTA Measure N&India: Exemption from additional import duty for patent or proprietary medicines
Description
On 1 March 2011, the government of India exempted all patented or proriertary medicines from the additional import duty levied upon them.The Customs Union of Russia, Belarus and Kazakhstan: Elimination of import tariff on heparin
Description
By the Customs Union Commission Decision # 480 from 18 November 2010 the import tariff on heparin (HS 3001) is removed - before 10 percent import tariff applied.United States of America: Bill to ban imports of goods for which there is no registered domestic agent
Description
A bill that was under consideration in the U.S.Venezuela: Devaluation of the Bolivar
Description
On 8 January 2010, the Venezuelan government announced the devaluation of the Bolivar. Instead of the existing fixed exchange rate at 2.15 Bs/US Dollar, the government now operates a two-tier system.Russia: Strategy of pharmaceutical industry development up to 2020
Description
The Ministry Decree from 23 October 2009 # 965 the strategy of pharmaceutical industry development up to 2020 was proved. It is aimed at increasing the competitiveness of the domestic pharma industry. The strategy has the following benchmarks:Mexico: Unilateral tariff elimination.
Description
